Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: multiplicity returned 15 record(s)
|
|
Monday, 08/01/2016
|
Is Type I error control for multiplicity really "out of the picture" in epidemiology?
Yueqin Zhao, FDA/CDER; Rima Izem, FDA; Mark Levenson, FDA
|
Adjustment for Multiplicity in Clinical Trials: When Is It Necessary and When Is It Not?
Boguang Zhen, FDA
9:15 AM
|
Multiplicity Adjustment Considerations in Designing a Confirmatory Oncology Clinical Trial with Multiple Endpoints
Di Li
9:20 AM
|
Optimizing Graphical Multiple Testing Schemes in Late-Phase Drug Development
Eric Nantz, Eli Lilly and Company
9:35 AM
|
Statistical Considerations for Cardiovascular Outcome Trials in Patients with T2DM
Maria Matilde Sanchez-Kam, Arena Pharmaceuticals
2:45 PM
|
A Bayesian Hierarchical Model for Pathway Analysis with Simultaneous Inference on Pathway-Gene-SNP Structure
Lei Zhang, The University of Texas at Dallas; Swati Biswas, The University of Texas at Dallas; Pankaj Choudhary, The University of Texas at Dallas
3:20 PM
|
|
Tuesday, 08/02/2016
|
The Covering Principle: A New Approach to Address Multiplicity in Hypothesis Testing
Huajiang Li, Allergan; Jihao Zhou, Allergan
8:35 AM
|
Adjustment for Categorization in Predictor Variables
Saptarshi Chatterjee, Northern Illinois University; Sanjib Basu, Northern Illinois University
9:20 AM
|
Bayesian Multiplicity Control for Multiple Graphs
Peter Mueller, The University of Texas at Austin; Riten Mitra, University of Louisville; Yuan Ji, NorthShore University HealthSystem
9:35 AM
|
Multiplicity Adjustment Strategy for Oncology Biomarker Trials
Shu-Chih Su, Merck; Jing Zhao, Merck
9:50 AM
|
Multiple Error Rate Concepts in Assessing Efficacy in Subgroups and Their Mixtures
Haiyan Xu, Johnson & Johnson; Jason Hsu, The Ohio State University
10:05 AM
|
Regulatory and Practical Considerations for an Adaptive Trial in the Context of Evaluating a Combination Product: An Example Using Two Human MAbs to Prevent Recurrence of CDI
Kenneth Koury, Merck Research Laboratories; Robert Tipping, Merck Research Laboratories
11:15 AM
|
|
|
